期刊文献+

改良皮下注射硼替佐米法治疗多发性骨髓瘤的临床观察 被引量:13

Clinical observation on multiple myeloma patients treated with modified subcutaneous injection of bortezomib
下载PDF
导出
摘要 [目的]探讨优化多发性骨髓瘤病人硼替佐米皮下注射技术,减少皮下注射不良反应的发生。[方法]选择多发性骨髓瘤病人使用硼替佐米皮下注射的病人66例,随机分为对照组和观察组,两组均按照左下腹、左大腿外侧、右大腿外侧、右下腹顺序进行皮下注射,观察组采用抽吸0.1 mL空气后,大腿外侧进针角度为40°~45°和腹部应用 Z路径注射,以及拔针后用棉球按压并延长按压时间的皮下注射技术,对照组按常规方法注射。观察两组病人注射30 min内疼痛情况及注射后24 h内注射局部情况,包括药液外渗、肿胀、红斑和硬结。[结果]观察组病人的疼痛评分以及注射局部发生药液外渗、肿胀、红斑的发生率均少于对照组(P〈0.01)。[结论]采用改良皮下注射技术能有效减少硼替佐米皮下注射引起的局部不良反应,减少病人痛苦。
出处 《护理研究(上旬版)》 2015年第7期2410-2412,共3页 Chinese Nursing Researsh
  • 相关文献

参考文献6

二级参考文献23

  • 1金益芝.术前护理干预对腹腔镜辅助阴式全子宫切除患者术后恢复的影响[J].当代护士(下旬刊),2010,17(9):71-72. 被引量:9
  • 2王桂清,于景芝,王晓萍.注射后残余药量的测定及临床研究[J].中华护理杂志,1995,30(12):740-742. 被引量:28
  • 3Mac Gabhann I.A comparison of two depot injection techniques.Nursing Standard,1998,12(37):39-42.
  • 4赵立华 张鸿燕.臀部肌肉注射并发症的预防及护理[J].黑龙江医学,2001,(1):64-64.
  • 5Pullen RL Jr.Administering medication by the Z-track method.Nursing,2005,35(7):24.
  • 6李小寒,尚少梅.护理基础学.4版.北京:人民出版社,2006:257-260.
  • 7余白玉.儿童肌肉注射体位与不良反应的临床观察[J].现代护理,2007,13(07Z):1914-1915. 被引量:6
  • 8Bross PF,Kane R,Farrell AT,et al.Approval summary for bortezomib for injection in the treatment of multiple myeloma.Clin Cancer Res,2004,10:3954 -3964.
  • 9Jagamath S,Durie BG,Wolf J,et al.Bortezomib therapy alme and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.Br J Haematol,2005,129:776-783.
  • 10Richardson PG,Barlogie B,Berenson NJ,et al.A phase 2 study of bortezomib in relapsed,refraetory myeloma.N Engl J Med,2003,348:2609 -2617.

共引文献39

同被引文献73

  • 1罗兰珠.喜辽妥联合硫酸镁冰敷治疗胺碘酮所致静脉炎的效果观察[J].心血管病防治知识(学术版),2019,0(17):47-48. 被引量:6
  • 2龚方,王晶.硼替佐米联合两种化疗方案治疗多发性骨髓瘤临床对比研究[J].医学信息,2017,30(3):134-135. 被引量:1
  • 3Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition [ J]. Cancer Research ,2007,67 ( 4 ) : 1783 - 1792.
  • 4Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high - dose dexamethasone for relapsed multiple myeloma [ J ]. The New England journal of medicine ,2005,352 (24) :2487 -2498.
  • 5Manochakian R, Miller KC, Chanan - Khan AA. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma [ J ]. The oncologist,2007,12 ( 8 ) :978 - 990.
  • 6Kumar SK, Rajkumar SV, Dispenzieri AA, et al. Improved survival in multiple myeloma and the impact of novel therapies [ J ]. Blood, 2008,111 (5) :2516 - 2520.
  • 7Greipp PR, Miguel JS, Durie BG, et al. International staging system for multiple myeloma [ J ]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005,23 (15) :3412 - 3420.
  • 8Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high - dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [ J ]. British Journal of Haematology, 1998,102 ( 5 ) : 1115 - 1123.
  • 9Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY -3021 study[J]. Haematologica,2015,100(5) :e207 -e210.
  • 10Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomlb in patients with relapsed multiple myeloma: a randomised, phase 3, non - inferiority study [ J ]. The lancet oncology, 2011,12 ( 5 ) :431 - 440.

引证文献13

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部